Beam Therapeutics Inc
BEAM34.600USD
+7.050+25.59%
Market hours （ET）Quotes delayed by 15 min
3.51BMarket Cap
LossP/E TTM
More Details of Beam Therapeutics Inc Company
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Beam Therapeutics Inc Info
Ticker SymbolBEAM
Company nameBeam Therapeutics Inc
IPO dateFeb 06, 2020
CEOEvans (John M)
Number of employees483
Security typeOrdinary Share
Fiscal year-endFeb 06
Address238 Main Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone18573278775
Websitehttps://beamtx.com/
Ticker SymbolBEAM
IPO dateFeb 06, 2020
CEOEvans (John M)
Company Executives of Beam Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-7434.00%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-67260.00%
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Independent Director
Independent Director
--
--
Ms. Kathleen E. Walsh
Ms. Kathleen E. Walsh
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Dr. Christine P. Bellon, Ph.D.
Dr. Christine P. Bellon, Ph.D.
Chief Legal Officer and Secretary
Chief Legal Officer and Secretary
--
--
Ms. Christi Shaw
Ms. Christi Shaw
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Giuseppe Ciaramella, Ph.D.
Dr. Giuseppe Ciaramella, Ph.D.
President
President
107.78K
-7434.00%
Dr. Amy Simon, M.D.
Dr. Amy Simon, M.D.
Chief Medical Officer
Chief Medical Officer
1.74K
-67260.00%
Mr. John M. Evans
Mr. John M. Evans
Chief Executive Officer, Principal Accounting Officer, Director
Chief Executive Officer, Principal Accounting Officer, Director
--
--
Mr. Graham K. Cooper
Mr. Graham K. Cooper
Independent Director
Independent Director
--
--
Dr. Mark C. Fishman, M.D.
Dr. Mark C. Fishman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Carole Ho, M.D.
Dr. Carole Ho, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
9.70M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.11%
ARK Investment Management LLC
10.88%
Farallon Capital Management, L.L.C.
9.92%
The Vanguard Group, Inc.
9.09%
BlackRock Institutional Trust Company, N.A.
6.68%
Other
52.33%
Shareholders
Shareholders
Proportion
Fidelity Management & Research Company LLC
11.11%
ARK Investment Management LLC
10.88%
Farallon Capital Management, L.L.C.
9.92%
The Vanguard Group, Inc.
9.09%
BlackRock Institutional Trust Company, N.A.
6.68%
Other
52.33%
Shareholder Types
Shareholders
Proportion
Investment Advisor
56.43%
Investment Advisor/Hedge Fund
20.11%
Hedge Fund
16.85%
Venture Capital
4.79%
Research Firm
2.41%
Individual Investor
1.27%
Bank and Trust
1.22%
Pension Fund
0.28%
Family Office
0.06%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
532
103.69M
102.18%
-12.40M
2025Q3
555
103.63M
115.87%
-3.47M
2025Q2
543
105.59M
104.59%
+6.88M
2025Q1
544
98.62M
86.09%
+12.05M
2024Q4
527
78.89M
102.08%
+2.21M
2024Q3
525
76.92M
104.62%
-27.93K
2024Q2
525
76.91M
100.89%
+164.00K
2024Q1
537
75.04M
97.79%
-4.82M
2023Q4
537
73.96M
95.46%
+409.36K
2023Q3
543
73.50M
97.66%
+2.85M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Fidelity Management & Research Company LLC
11.27M
11.11%
-1.26M
-10.04%
Sep 30, 2025
ARK Investment Management LLC
11.04M
10.88%
+628.70K
+6.04%
Sep 30, 2025
Farallon Capital Management, L.L.C.
10.06M
9.92%
+50.00K
+0.50%
Sep 30, 2025
The Vanguard Group, Inc.
9.23M
9.09%
-459.51K
-4.74%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.78M
6.68%
+54.70K
+0.81%
Sep 30, 2025
Amova Asset Management Co., Ltd.
4.83M
4.76%
+101.29K
+2.14%
Sep 30, 2025
ARCH Venture Partners
4.54M
4.47%
--
--
Sep 30, 2025
State Street Investment Management (US)
4.01M
3.95%
+370.39K
+10.18%
Sep 30, 2025
Bellevue Asset Management AG
2.89M
2.85%
--
--
Sep 30, 2025
Kynam Capital Management LP
2.52M
2.48%
+100.00K
+4.14%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
4.45%
Global X Genomics & Biotechnology ETF
2.42%
ARK Innovation ETF
2.3%
WisdomTree BioRevolution Fund
2.13%
Virtus LifeSci Biotech Clinical Trials ETF
0.97%
Franklin Genomic Advancements ETF
0.96%
State Street SPDR S&P Biotech ETF
0.84%
Harbor Health Care ETF
0.53%
Direxion Daily S&P Biotech Bull 3X Shares
0.51%
iShares Health Innovation Active ETF
0.3%
View more
ARK Genomic Revolution ETF
Proportion4.45%
Global X Genomics & Biotechnology ETF
Proportion2.42%
ARK Innovation ETF
Proportion2.3%
WisdomTree BioRevolution Fund
Proportion2.13%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.97%
Franklin Genomic Advancements ETF
Proportion0.96%
State Street SPDR S&P Biotech ETF
Proportion0.84%
Harbor Health Care ETF
Proportion0.53%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.51%
iShares Health Innovation Active ETF
Proportion0.3%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Beam Therapeutics Inc?
The top five shareholders of Beam Therapeutics Inc are:
Fidelity Management & Research Company LLC holds 11.27M shares, accounting for 11.11% of the total shares.
ARK Investment Management LLC holds 11.04M shares, accounting for 10.88% of the total shares.
Farallon Capital Management, L.L.C. holds 10.06M shares, accounting for 9.92% of the total shares.
The Vanguard Group, Inc. holds 9.23M shares, accounting for 9.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.78M shares, accounting for 6.68% of the total shares.
Fidelity Management & Research Company LLC holds 11.27M shares, accounting for 11.11% of the total shares.
ARK Investment Management LLC holds 11.04M shares, accounting for 10.88% of the total shares.
Farallon Capital Management, L.L.C. holds 10.06M shares, accounting for 9.92% of the total shares.
The Vanguard Group, Inc. holds 9.23M shares, accounting for 9.09% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 6.78M shares, accounting for 6.68% of the total shares.
What are the top three shareholder types of Beam Therapeutics Inc?
The top three shareholder types of Beam Therapeutics Inc are:
Fidelity Management & Research Company LLC
ARK Investment Management LLC
Farallon Capital Management, L.L.C.
Fidelity Management & Research Company LLC
ARK Investment Management LLC
Farallon Capital Management, L.L.C.
How many institutions hold shares of Beam Therapeutics Inc (BEAM)?
As of 2025Q4, 532 institutions hold shares of Beam Therapeutics Inc, with a combined market value of approximately 103.69M, accounting for 102.18% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -13.69%.
What is the biggest source of revenue for Beam Therapeutics Inc?
In FY2025Q3, the -- business generated the highest revenue for Beam Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
